| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Lefkoff Kyle is a Director at Viridian Therapeutics, Inc.\DE. Recent SEC Form 4 filings include 0 buys and 10 sells.
Estimated insider holdings value: $7.7M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2017 | VRDN Viridian Therapeutics, Inc.\de | Director | Sell | 5,800 | $14.34 | $83,190.44 | -0.6% | |
| Mar 8, 2017 | VRDN Viridian Therapeutics, Inc.\de | Director | Sell | 15,000 | $15.40 | $230,977.44 | -1.0% | |
| Feb 28, 2017 | VRDN Viridian Therapeutics, Inc.\de | Director | Sell | 10,258 | $13.89 | $142,518.79 | -0.7% | |
| Feb 23, 2017 | VRDN Viridian Therapeutics, Inc.\de | Director | Sell | 5,902 | $14.14 | $83,451.71 | -0.6% |